GLUE Monte Rosa Therapeutics, Inc.
$12.65
Monte Rosa Therapeutics, Inc. (GLUE) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Insider signal
In line
Selling ran in line with GLUE's own trailing one-year pace, with 54% of sale value under a prearranged plan.
Cluster activity
0 buyers in the last 30 days
0 buyers in the last 90 days
5 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
7
36 transactions
Purchases
$0
0 shares
Sales
$4.1M
207,811 shares
Net activity
-$4.1M
purchases less sales
How much of that selling was preplanned? 54% planned / 46% discretionary
10b5-1 plan sales
$2.2M
21 transactions · 106,170 shares
Discretionary sales
$1.9M
15 transactions · 101,641 shares
Largest single sale: $642.7K.
Where they traded
Buy
Sell
Dot area is proportional to transaction value.
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Warmuth Markus | President & CEO | Sell | 9,500 | $23.18 | $220.2K | 585,038 −1.6% of holding | |
| Champoux Jennifer | Chief Operating Officer | Sell 10b5-1 | 4,351 | $23.38 | $101.7K | 62,371 −6.5% of holding | |
| Townson Sharon 2 fills | Chief Scientific Officer | Sell 10b5-1 | 6,000 | $23.31 | $139.8K | 68,245 −8.1% of holding | |
| Janku Filip | Chief Medical Officer | Sell 10b5-1 | 5,407 | $24.50 | $132.5K | 60,612 −8.2% of holding | |
| Manning Anthony M. | Director | Sell | 10,000 | $23.11 | $231.1K | None left | |
| Janku Filip | Chief Medical Officer | Sell 10b5-1 | 6,000 | $22.95 | $137.7K | 59,992 −9.1% of holding | |
| Janku Filip | Chief Medical Officer | Sell 10b5-1 | 30,000 | $21.42 | $642.7K | 59,992 −33.3% of holding | |
| Janku Filip | Chief Medical Officer | Sell 10b5-1 | 11,845 | $20.22 | $239.5K | 59,992 −16.5% of holding | |
| Townson Sharon | Chief Scientific Officer | Sell 10b5-1 | 3,000 | $20.00 | $60.0K | 67,845 −4.2% of holding | |
| Champoux Jennifer | Chief Operating Officer | Sell 10b5-1 | 2,175 | $20.00 | $43.5K | 62,371 −3.4% of holding | |
| Townson Sharon | Chief Scientific Officer | Sell 10b5-1 | 3,000 | $19.00 | $57.0K | 67,845 −4.2% of holding | |
| Champoux Jennifer | Chief Operating Officer | Sell 10b5-1 | 2,176 | $19.00 | $41.3K | 62,371 −3.4% of holding | |
| Warmuth Markus 2 fills | President & CEO | Sell 10b5-1 | 5,466 | $19.44 | $106.3K | 595,006 −0.9% of holding | |
| Townson Sharon | Chief Scientific Officer | Sell 10b5-1 | 6,000 | $19.87 | $119.2K | 67,845 −8.1% of holding | |
| Champoux Jennifer | Chief Operating Officer | Sell 10b5-1 | 2,175 | $20.00 | $43.5K | 62,371 −3.4% of holding | |
| Champoux Jennifer | Chief Operating Officer | Sell 10b5-1 | 2,176 | $19.00 | $41.3K | 62,371 −3.4% of holding | |
| Manning Anthony M. | Director | Sell | 10,000 | $18.01 | $180.1K | None left | |
| Warmuth Markus | President & CEO | Sell 10b5-1 | 5,467 | $18.92 | $103.4K | 600,004 −0.9% of holding | |
| Warmuth Markus | President & CEO | Sell | 8,000 | $17.64 | $141.1K | 605,471 −1.3% of holding | |
| Nickson Philip | Chief Business & Legal Officer | Sell | 5,845 | $17.69 | $103.4K | 55,000 −9.6% of holding | |
| Dunn Edmund | Principal Accounting Officer | Sell | 139 | $17.96 | $2.5K | 22,554 −0.6% of holding | |
| Warmuth Markus | President & CEO | Sell 10b5-1 | 5,466 | $17.92 | $98.0K | 613,471 −0.9% of holding | |
| Dunn Edmund | Principal Accounting Officer | Sell | 536 | $17.50 | $9.4K | 22,693 −2.3% of holding | |
| Dunn Edmund | Principal Accounting Officer | Sell | 25,164 | $18.10 | $455.5K | 22,693 −52.6% of holding | |
| Janku Filip | Chief Medical Officer | Sell | 9,189 | $19.50 | $179.2K | 65,837 −12.2% of holding | |
| Warmuth Markus 3 fills | President & CEO | Sell 10b5-1 | 5,466 | $23.49 | $128.4K | 620,696 −0.9% of holding | |
| Warmuth Markus | President & CEO | Sell | 10,135 | $15.17 | $153.7K | 624,403 −1.6% of holding | |
| Townson Sharon | Chief Scientific Officer | Sell | 3,155 | $15.17 | $47.9K | 67,845 −4.4% of holding | |
| Janku Filip | Chief Medical Officer | Sell | 3,155 | $15.17 | $47.9K | 75,026 −4% of holding | |
| Nickson Philip | Chief Business & Legal Officer | Sell | 3,155 | $15.17 | $47.9K | 60,845 −4.9% of holding | |
| Champoux Jennifer | Chief Operating Officer | Sell | 2,629 | $15.17 | $39.9K | 62,371 −4% of holding | |
| Dunn Edmund | Principal Accounting Officer | Sell | 1,039 | $15.17 | $15.8K | 22,693 −4.4% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.